Well Referenced

Tag: HELIXOR

Safety of Intravenous Application of Mistletoe (Viscum album L.) Preparations in Oncology: An Observational Study

This large-scale observational study evaluated the safety of intravenous mistletoe preparations (Helixor, Abnoba viscum, Iscador) in 475 oncology patients. Over 4,500 infusions were analyzed. Adverse drug reactions (ADRs) were reported in 4.6% of patients, with 59.4% of these being mild and 40.6% moderate; no severe ADRs were observed. ADRs occurred

Read More »
June 26, 2025 No Comments

Use and safety of intratumoral application of European mistletoe (Viscum album L) preparations in Oncology

This study investigates the safety and adverse effects of intratumoral (IT) mistletoe injections in 123 cancer patients, examining the incidence and severity of adverse drug reactions (ADRs) from 862 injections using preparations like Abnoba Viscum and Helixor. The study found that 21.1% of patients experienced mild ADRs, including localized reactions

Read More »
June 26, 2025 No Comments

Impact of Complementary Treatment of Breast Cancer Patients With Standardized Mistletoe Extract During Aftercare: A Controlled Multicenter Comparative Epidemiological Cohort Study

This 2008 multicenter cohort study (Anticancer Research, PMID: 18383896) evaluated the impact of standardized mistletoe extract (HELIXOR) as a complementary therapy in the aftercare of 681 breast cancer patients across 53 hospitals and practices in Germany. Among them, 167 received mistletoe extract, while 514 served as controls. Over approximately five

Read More »
June 26, 2025 No Comments